New California Law Could Benefit Mesothelioma Plaintiffs
A recently amended California law will now allow the estates of deceased plaintiffs, including mesothelioma patients, to collect pain and suffering damages. Previously, only the person who sustained bodily injury could recover pain and suffering damages. These damages are often the largest sums of money at stake in many mesothelioma lawsuits. When it becomes law on Jan. 1, Senate Bill 447 will expand the range of recoverable damages and eliminate long-standing restrictions. The amended statute, signed Oct. 1, allows California to join 45 other states that permit the recovery of noneconomic damages for an assort...
Source: Asbestos and Mesothelioma News - October 25, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Johnson & Johnson Sending Talc Cases to Bankruptcy Court
As expected, Johnson & Johnson has unloaded its burgeoning talc-related liabilities on a new subsidiary that filed for Chapter 11 bankruptcy protection on Oct. 14. The controversial move, which confirmed the fears of many personal injury attorneys, is an attempt by J&J to more easily resolve the thousands of current and future lawsuits claiming that its talc products have caused serious medical problems, including ovarian and mesothelioma cancers. Most of the claims contend that talc in the products was contaminated with toxic asbestos fibers. The filing, in U.S. Bankruptcy Court in the Western District of...
Source: Asbestos and Mesothelioma News - October 18, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Courts Seeing More Secondary Asbestos Exposure Lawsuits
Secondary exposure to toxic asbestos has declined dramatically in recent decades, but known cases of malignant mesothelioma caused by that type of asbestos exposure have continued to climb. Increasing awareness of the rare cancer has led to the contrasting trends and an expected rise in personal injury lawsuits involving secondary asbestos exposure. “One of the reasons is that we are getting better at diagnosing the disease,” attorney Daniel Wasserberg, who specializes in asbestos litigation, told The Mesothelioma Center at asbestos.com. “Years ago, a woman with classic mesothelioma symptoms, but wi...
Source: Asbestos and Mesothelioma News - October 18, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

War journalism: an occupational exposure - Magnavita N, Congedo MT, Di Prinzio RR, Iuliano A.
Apart from the risk of accidents, war theatres present a hazard related to numerous long-lasting toxic agents. For 10 years, a>60-year-old male journalist worked in war theatres in the Far and Near East where he was exposed to asbestos and other toxic sub... (Source: SafetyLit)
Source: SafetyLit - October 18, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Johnson & Johnson Takes Steps to Equitably Resolve All Current and Future Talc Claims
NEW BRUNSWICK, N.J., October 14, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that LTL Management LLC (LTL), a newly created and separate subsidiary of Johnson & Johnson, that was established to hold and manage claims in the cosmetic talc litigation, has filed for voluntary Chapter 11 bankruptcy protection. This filing is intended to resolve all claims related to cosmetic talc in a manner that is equitable to all parties, including any current and future claimants. Johnson & Johnson and its other affiliates did not file for bankruptcy protection and will continue to operate their bus...
Source: Johnson and Johnson - October 14, 2021 Category: Pharmaceuticals Tags: Latest News Source Type: news

EPA Settles Lawsuits, Agrees to Broader Asbestos Risk Evaluations
Facing legal pressure from health and advocacy organizations, the U.S. Environmental Protection Agency has agreed to broaden its ongoing Risk Evaluation for Asbestos under the Toxic Substances Control Act. An agreement to settle two lawsuits – both alleging inadequate evaluation of toxic asbestos – was filed Oct. 13 in the U.S. Court of Appeals for the Ninth Circuit in San Francisco. The Asbestos Disease Awareness Organization was the lead plaintiff in the risk evaluation litigation and was joined by health organizations, scientists and doctors, including acclaimed thoracic surgeon Dr. Raja Flores of Moun...
Source: Asbestos and Mesothelioma News - October 14, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Researchers Open Phase I Clinical Trial of Cryoablation with Keytruda
Memorial Sloan Kettering Cancer Center in New York City has opened a novel clinical trial that combines the immunotherapy drug Keytruda with cryoablation for patients with unresectable malignant mesothelioma. The phase I trial opened in September and will be available at seven Memorial Sloan Kettering locations in the New York City/New Jersey area. Cryoablation, which is also known as cryotherapy or cryosurgery, is a treatment that freezes localized tumors with argon gas or liquid nitrogen. It has been used effectively with liver, kidney and prostate cancers, but its use with mesothelioma has been limited because of ...
Source: Asbestos and Mesothelioma News - October 14, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

New Opdivo/Yervoy Mesothelioma Clinical Trial Begins Soon
A novel clinical trial involving the immunotherapy combination of Opdivo and Yervoy will open soon in Chicago. The goal is to study the drugs’ efficacy when added to surgery for patients with peritoneal mesothelioma cancer. The single-center, phase II clinical trial follows a recent report detailing the impressive three-year effectiveness of the drug combination when used for unresectable pleural mesothelioma. Bristol Myers Squibb manufactures Opdivo and Yervoy, known generically as nivolumab and ipilimumab. The U.S. Food and Drug Administration approved the combination for pleural mesothelioma in 2020, making ...
Source: Asbestos and Mesothelioma News - October 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Virtual Symposium to Focus on Mesothelioma Treatment Advances
Sylvester Comprehensive Cancer Center of South Florida will host its free virtual First Miami International Mesothelioma Symposium on November 6, 2021. The Mesothelioma Program at the Sylvester Comprehensive Cancer Center has grown to become one of America’s leaders in this specialized field, attracting a wide range of expertise for its upcoming virtual symposium. “Mesothelioma is such a rare disease that we really have to bring in experts from around the world to get a true picture of what’s coming next. And I think we’ve done that with our program,” medical oncologist Dr. Estelamari Ro...
Source: Asbestos and Mesothelioma News - October 5, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

Asbestos Cleanup Moving Forward at EPA ’s Libby Superfund Site
Decontamination efforts in Libby, Montana – the largest asbestos cleanup project in American history – moved another step closer to completion this month, according to the U.S. Environmental Protection Agency. The Montana Department of Environmental Quality and the EPA have determined that restoration efforts are complete in another major segment of the original Libby Asbestos Superfund site. A Superfund designation is defined as a federal public health emergency. Contamination at the site stemmed from the W.R. Grace & Co. vermiculite mine, once the lifeblood of the area, that spread asbestos dust th...
Source: Asbestos and Mesothelioma News - October 4, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Study Shows Access to Care Often Difficult for Mesothelioma Patients
When it comes to malignant pleural mesothelioma, not everyone is treated equally. A disparity in access to care makes the difference in mesothelioma treatment quite dramatic, according to the University of Miami’s Sylvester Comprehensive Cancer Center. “Patients without access to expert multidisciplinary care at high-volume, academic facilities are being inappropriately undertreated for their disease,” medical oncologist Dr. Estelamari Rodriguez told The Mesothelioma Center at Asbestos.com. “The access is not adequate as it should be for everyone.” Rodriguez led a recent study at Univers...
Source: Asbestos and Mesothelioma News - September 28, 2021 Category: Environmental Health Authors: Chris Elkins Source Type: news

Nivo/Ipi Combo Now'Standard of Care' in Mesothelioma Nivo/Ipi Combo Now'Standard of Care' in Mesothelioma
Patients with malignant pleural mesothelioma have a marked and sustained overall survival benefit with nivolumab and ipilimumab vs chemotherapy, even if they discontinue treatment.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 17, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Cell therapy partnership between Bay Area biotechs offers hope to cancer patients
Imagine a world in which physicians can confidently cure cancer. Two Bay Area life sciences companies are working together to make this vision a reality. Atara Biotherapeutics Inc., founded in 2012, is developing a pipeline of cell therapies to treat various types of cancer and autoimmune diseases. Bayer is licensing Atara’s cutting-edge cell therapies that t arget certain types of aggressive tumors including mesothelioma, pancreatic, ovarian and non-small-cell lung cancer. “With cancer therapies,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 16, 2021 Category: Pharmaceuticals Authors: Lauren Lawley Head Source Type: news

Cancer symptoms: The sound of your voice could predict lung cancer diagnosis
LUNG cancer can develop from inhaling toxins, such as secondhand smoke, asbestos, diesel exhaust, or chromium compounds. In the very early stages, there will likely be no warning that a tumour is growing inside of you. (Source: Daily Express - Health)
Source: Daily Express - Health - September 16, 2021 Category: Consumer Health News Source Type: news

2021 ADAO Asbestos Awareness Conference Runs Sept. 17-18
The 16th Annual International Asbestos Awareness and Prevention Conference takes place Sept. 17-18, featuring 40 speakers from seven countries plus the first-ever Art, Advocacy and Shared Stories film festival. This virtual event is open to all free of charge, requiring only an online registration. It is designed to educate the public about the dangers of asbestos, intensify efforts to ban asbestos, and aid in research to improve treatment for asbestos diseases, including mesothelioma cancer. Sponsoring the event is the Asbestos Disease Awareness Organization, an independent nonprofit regarded as the world’s le...
Source: Asbestos and Mesothelioma News - September 16, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Research, COVID Findings Featured at IASLC Conference
This study, performed during the pre-vaccine period of the pandemic, once again demonstrates the importance of vaccination against COVID-19,” said Dr. Susana Cedres, a medical oncologist with Vall d’Hebron Hospital. “Malignant pleural mesothelioma patients are particularly vulnerable to COVID-19.” Cedres said since the subsequent rollout of the COVID-19 vaccines, no positive cases have been attributed to pleural mesothelioma patients at the hospital. The average age of the seven patients was 62. All had the epithelioid histology of mesothelioma and two were receiving oncologic treatment at the...
Source: Asbestos and Mesothelioma News - September 15, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Ramucirumab Shows Survival Benefits with Pleural Mesothelioma
Adding the drug ramucirumab to gemcitabine chemotherapy worked especially well in a recent clinical trial involving second-line treatment for patients with pleural mesothelioma. Ramucirumab, an immunotherapy drug also known by the brand name Cyramza, is a monoclonal antibody that works by targeting and restricting a protein that stimulates blood vessel growth within tumors. Impressive results in the phase II clinical trial moved the drug combination closer to filling the long-standing void for a second-line mesothelioma treatment. The Lancet Oncology recently published results of the study, which was conducted in ...
Source: Asbestos and Mesothelioma News - September 13, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

What 9/11 Survivors and First Responders Have Taught Us About Public Health in the 20 Years Since the Attacks
Dr. David Prezant was knocked fully airborne at 9:59 on the morning of Sept. 11, 2001. He didn’t see the impact coming, but he felt it when it hit—and it nearly killed him. Little more than an hour earlier, Prezant, then the deputy chief medical officer of the Fire Department of New York, was headed for his usual workplace at the FDNY’s Office of Medical Affairs, just across the Manhattan Bridge in Brooklyn. He had already heard that a plane had hit the North Tower of the World Trade Center, and he reckoned that it was an accident. By the time he reached his office, however, the South Tower had been struc...
Source: TIME: Health - September 10, 2021 Category: Consumer Health News Authors: Jeffrey Kluger and Tara Law Tags: Uncategorized healthscienceclimate Source Type: news

New Report Details 9/11 Health Effects on FDNY Firefighters
A recent report from the Fire Department of New York World Trade Center Health Program outlines the 9/11-related health effects firefighters are dealing with 20 years later. Approximately 410,000 first responders spent the days and weeks after 9/11 inhaling toxic materials as they helped save lives from the collapse of the Twin Towers. Almost 3,000 people died on Sept. 11, 2001, but in the 20 years since, another 4,343 survivors have died due to related health effects. FDNY has felt the impact of delayed illness, as well. While 343 FDNY firefighters died on 9/11, another 254 have died since then from 9/11-related dis...
Source: Asbestos and Mesothelioma News - September 9, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

NYC Mayor Waives Asbestos Fees in Response to Hurricane Ida
New York City Mayor Bill de Blasio has waived fees for asbestos removal as part of the recovery response to Hurricane Ida. The mayor also waived the seven-day advance notice requirement for asbestos projects. De Blasio signed Emergency Executive Order No. 235 on Sept. 7, allowing the New York City Department of Environmental Protection and Department of Buildings to waive fees and advance notification requirements for various permits and applications related to storm damage repair. The order remains in effect for five days unless it is terminated or modified. These measures are intended to relieve an additional burde...
Source: Asbestos and Mesothelioma News - September 9, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Treatment Program Expanding in Central Florida
When he first joined AdventHealth Orlando in 2019, thoracic surgeon Dr. Marcelo DaSilva wondered just how successful he could be in creating a mesothelioma specialty center in Central Florida. Now he knows. DaSilva was initially hoping to create a program that would allow Florida mesothelioma patients to stay closer to home – instead of traveling across the country – and still get the best possible treatment for this rare, tough-to-treat malignancy. But he’s already done considerably more. His vision has grown, and so has his program. More patients will benefit greatly. DaSilva recently expand...
Source: Asbestos and Mesothelioma News - September 8, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

How lung cancer arises in non-smokers revealed
Lung cancer is the leading cause of cancer-related deaths worldwide. Environmental risk factors, such as exposure to radon, air pollution, and asbestos, or having had previous lung diseases, may explain some lung cancers among never smokers, but scientists still don't know what causes the majority of these cancers. (Source: The Economic Times)
Source: The Economic Times - September 8, 2021 Category: Consumer Health News Source Type: news

Study: Pleural Mesothelioma Treatment Effective with Peritoneal Disease
We report the first real-world evidence regarding clinical outcomes for a cohort of patients with advanced MPeM receiving ICIs,” the MD Anderson study authors wrote. “Our results provide much-needed data supporting the role of ICIs in patients with this rare disease, who cannot participate in clinical trials and otherwise have no or limited treatment options.” The post Study: Pleural Mesothelioma Treatment Effective with Peritoneal Disease appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - August 31, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Judge Moves Johnson & Johnson Closer to Potential Reorganization
Johnson & Johnson is closer to unloading its talc-related liabilities onto a new subsidiary that could subsequently declare Chapter 11 bankruptcy and dramatically alter the thousands of lawsuits the company is facing. A U.S. Bankruptcy Court judge in the District of Delaware declined requests last week from a panel of personal injury lawyers to prohibit Johnson & Johnson from exercising that option. J&J is facing more than 34,000 lawsuits that link its talc-based products to cancer, the majority of which are ovarian cancer. A small fraction of those lawsuits involve malignant mesothelioma. Most of the ...
Source: Asbestos and Mesothelioma News - August 31, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Researchers Study New Immunotherapy Combination for Mesothelioma
The immunotherapy combination of tremelimumab and durvalumab has shown surprising efficacy, particularly as a second-line treatment option for patients with pleural mesothelioma, according to a recent study. Its effectiveness, comparable to a similar combination which was approved in 2020 by the U.S. Food and Drug Administration, further illustrated the new direction for future treatment of mesothelioma. Chemotherapy will no longer be the stand-alone, standard-of-care treatment for most patients. “Promising results have emerged on the use of targeted treatment with immune checkpoint inhibitors (ICI), particu...
Source: Asbestos and Mesothelioma News - August 30, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mesothelioma Olaparib Clinical Trial Targets Genetic Mutation
The mesothelioma program at University of Chicago Medicine is recruiting patients for its latest clinical trial involving olaparib, an oral chemotherapy drug targeting cancer-driven genetic mutations. This single-center, phase II clinical trial is open to patients with either pleural mesothelioma or peritoneal mesothelioma. Olaparib, also known by the brand name Lynparza, works by repairing or controlling specific gene mutations. It is known as a protein inhibitor and has been approved by the U.S. Food and Drug Administration for use with breast and ovarian cancers. Mesothelioma, a rare malignancy caused by exposu...
Source: Asbestos and Mesothelioma News - August 24, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Social Security Adds Pericardial Mesothelioma to Disabilities List
The U.S. Social Security Administration has added pericardial mesothelioma to its Compassionate Allowances list, accelerating the disabilities application process for this very rare cancer. Its decision was prompted by the work of Missy Miller, medical outreach director at The Mesothelioma Center. She made the request with the Social Security disability office almost a year ago on behalf of a patient. The Compassionate Allowances program is reserved for severe medical diseases and conditions that automatically meet Social Security standards for disability benefits. It cuts short the often drawn-out application proces...
Source: Asbestos and Mesothelioma News - August 18, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

1990 to 2017 Saw Increase in Global Incidence of Mesothelioma
WEDNESDAY, Aug. 11, 2021 -- Incident cases of mesothelioma and deaths associated with mesothelioma increased worldwide during 1990 to 2017, according to a study published online Aug. 11 in JAMA Network Open. Zhen Zhai, M.D., from Zhejiang... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 11, 2021 Category: Pharmaceuticals Source Type: news

Duke Study Suggests Radiation Does Not Extend Mesothelioma Survival
A dual registry analysis by the esteemed Duke University Medical Center has concluded that adjuvant hemithoracic radiation does not improve survival when combined with aggressive surgery for patients with malignant pleural mesothelioma. Although the U.S. National Comprehensive Cancer Network and the European Society for Medical Oncology recommend the adjuvant radiation – as do many specialists – the Duke research team has challenged the conventional treatment with this report. “The receipt of adjuvant hemithoracic radiation was not associated with improved survival when compared to no radiation,&rdq...
Source: Asbestos and Mesothelioma News - August 9, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Study: Treatment at Academic Facilities Extends Mesothelioma Survival
More than half of patients with peritoneal mesothelioma cancer in the United States are being treated at community hospitals, sacrificing the chance to extend survival at an academic/research facility. Too many die sooner than they should. A medical research team at Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, has shown that median survival is more than twice as long for patients treated at an academic facility compared to those at a community hospital. “Malignant peritoneal mesothelioma patients may be better served at experienced, academic centers,” the authors ...
Source: Asbestos and Mesothelioma News - August 4, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

J & J Facing Scrutiny from Congress, Black Women ’s Organization
Plaintiff attorneys and congressional leaders have renewed their push against Johnson & Johnson and its allegedly toxic, talc-based powder products, questioning motives and demanding answers, according to various media outlets. A committee of attorneys filed a restraining order in U.S. District Court in Wilmington, Delaware, July 27, hoping to prevent J&J’s potential plan to unload its talc-related liabilities on a new subsidiary that would subsequently file for bankruptcy. The next day, the U.S. House of Representatives Committee on Oversight and Reform delivered a letter to J&J’s chief execu...
Source: Asbestos and Mesothelioma News - August 2, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Almost Every Doctor Recommends Sunscreen. So Why Don ’t We Know More About Its Safety?
Each year, as Memorial Day approaches, Holly Thaggard braces herself for the headlines. About how sunscreen may be damaging coral reefs. About the possible flammability of spray-on sunscreen. Headlines—as there were this year—about how sunscreen contains chemicals that could harm your health. “This has happened every single year for the last decade of my life,” says Thaggard, founder of Texas-based Supergoop, a sunscreen company that brands itself as reef-safe and free of hundreds of potentially problematic ingredients. This year, the is-sunscreen-dangerous news cycle started in May, when Valisure, ...
Source: TIME: Health - August 2, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthscienceclimate Public Health Source Type: news

FDA Grants Orphan Drug Designation to Novel Mesothelioma Treatment
The U.S. Food and Drug Administration has granted orphan drug designation to ONCOFID-P for the treatment of malignant pleural mesothelioma, a step toward another potential therapy option for patients. ONCOFID-P is an innovative drug conjugate already in advanced clinical development for the treatment of invasive bladder cancer. The mesothelioma designation is based on preclinical data showing high antitumor activity in laboratory and mice models. Fidia Farmaceutici, a multinational research company based in Italy, announced the latest FDA designation, which is designed to encourage the development of novel drugs, par...
Source: Asbestos and Mesothelioma News - July 28, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Researcher Hopes to Improve Tumor Treating Fields for Mesothelioma
Dr. Maurizio D’Incalci already has seen Tumor Treating Fields working for patients with malignant pleural mesothelioma, and applauded the U.S. Food and Drug Administration’s approval of the treatment in 2019. He also knows the therapy is only scratching the surface of its vast potential and could be even more effective. He wants to help improve it. D’Incalci, a heralded biomedical science professor at Humanitas University in Milan, Italy, has begun a study exploring various drug combinations that could have a positive, synergistic effect with Tumor Treating Fields for mesothelioma. “There m...
Source: Asbestos and Mesothelioma News - July 27, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

CAR T-Cell Therapy Showing Promise with Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center continues its drive toward a future that may involve innovative CAR T-cell therapy as part of standard-of-care treatment for malignant pleural mesothelioma. The latest step was a clinical trial exploring a first-in-human, intrapleural-administered CAR T-cell therapy used in combination with pembrolizumab, a well-known immunotherapy drug also known by the brand name Keytruda. Results were impressive, including a 23.9-month median overall survival and an 83% one-year survival rate for patients. Cancer Discovery published the single-center study results July 15. “There is ...
Source: Asbestos and Mesothelioma News - July 22, 2021 Category: Environmental Health Authors: Chris Elkins Source Type: news

Johnson & Johnson Weighs Options for Talc Liabilities
Johnson & Johnson is considering the creation of a new subsidiary to absorb its widespread asbestos liabilities, according to reports in The Wall Street Journal and other news outlets. The J&J subsidiary would then declare Chapter 11 bankruptcy, potentially saving the multinational corporation billions of dollars. Reuters News Service also reported the subsidiary possibility, citing unnamed personal injury attorneys who learned of the option while negotiating their current claims with J&J officials. A spokesperson for Johnson & Johnson would not confirm the reports.  “Johnson & J...
Source: Asbestos and Mesothelioma News - July 22, 2021 Category: Environmental Health Authors: Chris Elkins Source Type: news

New Drug Combination Shows Promise for Peritoneal Mesothelioma
Researchers at MD Anderson Cancer Center in Houston have uncovered a new, promising treatment option for patients with peritoneal mesothelioma, potentially filling a gaping void that exists today. The immunotherapy drug combination of Tecentriq and Avastin, known generically as atezolizumab and bevacizumab, respectively, showed unusual efficacy in a recent study of 20 patients with this rare cancer. Although some patients have previously found significant success and extended survival with the cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combination, or HIPEC, those with unresectable disease ha...
Source: Asbestos and Mesothelioma News - July 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Medicare Collection Agency Sets Sights on Asbestos Trusts
A prominent Medicare services collection agency is taking aim at an estimated 60 viable asbestos trust funds, citing a failure to divulge settlement payments and deliver reimbursement to providers for health care services. Asbestos trusts are designed to compensate victims of diseases caused by exposure to asbestos, most notably malignant mesothelioma, a rare cancer with no definitive cure. MSP Recovery LLC, a leading Medicare/Medicaid recovery specialist, filed the first lawsuit last week against the J.T. Thorpe Settlement Trust, according to a report in The Wall Street Journal. J.T. Thorpe Inc. is a former indus...
Source: Asbestos and Mesothelioma News - July 20, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Drug combination shows meaningful responses for malignant peritoneal mesothelioma patient
(University of Texas M. D. Anderson Cancer Center) A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 14, 2021 Category: Cancer & Oncology Source Type: news

Mesothelioma Research Grants Focus on Immunotherapy
This study will start with comparisons in tumor-bearing animals treated with immunotherapy. Future drug targets will be based on the differences that are found. The goal is to find drugs that can prevent side effects while preserving robust anti-tumor response. The post Mesothelioma Research Grants Focus on Immunotherapy appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - July 12, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

GPS Vaccine Plus Opdivo Shows Promise for Pleural Mesothelioma
A novel, targeted cancer vaccine combined with the immunotherapy drug Opdivo has shown surprising efficacy for mesothelioma patients whose disease no longer responds to standard chemotherapy. In a phase I clinical trial at Memorial Sloan Kettering Cancer Center, the galinpepimut-S vaccine, also known as GPS, has produced an impressive, anti-tumor synergy with Opdivo, based upon early data. GPS targets the WT1 protein, which is expressed in high levels of various cancers but rarely seen in normal adult cells. The protein has been especially resistant to standard chemotherapy. The vaccine works by inducing a powerfu...
Source: Asbestos and Mesothelioma News - June 29, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Mayo Clinic Opens Novel Clinical Trial for Mesothelioma
Researchers at the much-acclaimed Mayo Clinic in Rochester, Minnesota, have opened the first clinical trial for mesothelioma patients that combines a recently approved immunotherapy treatment with targeted radiation. Potential for extending survival is there. This single-center phase I clinical trial opens June 24, and is expected to enroll at least 20 participants. It will study the safety and effectiveness of stereotactic body radiation therapy, known as SBRT, when added to the immunotherapy combination of Opdivo and Yervoy. “The reasoning behind this study is that we need to build upon the success we&rsqu...
Source: Asbestos and Mesothelioma News - June 23, 2021 Category: Environmental Health Authors: Lynette Zilio Source Type: news

Clinical Trial Shows Benefits of Vinorelbine for Mesothelioma
Mesothelioma specialist Dr. Dean Fennell has strongly endorsed the use of vinorelbine as a second-line treatment for patients with relapsed disease. He was the lead investigator in a recent phase II clinical trial studying the efficacy of vinorelbine for patients whose pleural mesothelioma cancer had progressed after traditional platinum-based chemotherapy. Fennell, who is chair of thoracic and medical oncology at University of Leicester and University Hospitals in the United Kingdom, has based his belief on the multicenter trial involving 154 mesothelioma patients with relapsed disease. “Doctors should now ...
Source: Asbestos and Mesothelioma News - June 21, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

ONCOS-102 Vaccine Showing Impressive Results for Mesothelioma
The novel immunotherapy vaccine ONCOS-102 may become the answer for the large percentage of mesothelioma cancer patients who fail to respond to a recently approved checkpoint inhibitor combination of treatment. ONCOS-102, a genetically modified oncolytic adenovirus, showed an overall survival rate of between 21.9 and 25 months in a randomized phase II clinical trial when combined with standard chemotherapy in a first-line setting. By comparison, patients in the trial receiving only standard chemotherapy had a median survival of just 13.5 months. The vaccine is the lead product of Targovax, a small Scandinavian bio...
Source: Asbestos and Mesothelioma News - June 17, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Breath Test Predicts Immunotherapy Response to Mesothelioma
Researchers in the Netherlands are touting a novel breath test for mesothelioma patients to better predict response to the immunotherapy combination of nivolumab and ipilimumab that was approved recently for first-line treatment of the disease. They believe exhaled breath analysis using electronic technology – known as eNose – can differentiate between responders and nonresponders before treatment begins, saving many patients from unnecessary side effects. There currently are no biomarkers for mesothelioma that can accurately predict the effectiveness of these types of immunotherapy drugs, known as immune...
Source: Asbestos and Mesothelioma News - June 10, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

EPA Agrees to Address Asbestos Data-Collection Deficiencies
Under pressure from a multistate coalition, the U.S. Environmental Protection Agency has agreed to tighten its data collection process for asbestos, moving the country another step closer to banning the toxic substance. The agreement comes six months after a U.S. District Court judge in California ruled the EPA must improve its ineffective data collection on asbestos imports, and two years after attorneys general in multiple states challenged in court the EPA’s lack of more restrictive asbestos regulations. “The longtime failure of the EPA to regulate asbestos is an environmental injustice and public heal...
Source: Asbestos and Mesothelioma News - June 9, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Immunotherapy Combo Now Approved for First-Line Mesothelioma in EU Immunotherapy Combo Now Approved for First-Line Mesothelioma in EU
Nivolumab plus ipilimumab showed superior overall survival versus standard-of-care chemotherapy in patients with unresectable malignant mesothelioma.News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

U.S. Supreme Court Rejects J & J Appeal of $2 Billion Talc Verdict
The U.S. Supreme Court rejected a request June 1 from Johnson & Johnson to consider overturning a $2.1 billion award to 22 women who blamed the company’s asbestos-contaminated talcum powder products for causing ovarian cancer. With the Supreme Court declining to consider it, a Missouri state court ruling from 2018 that originally awarded $4.69 billion remains in place. A Missouri court of appeals reduced the award in 2020 to $2.1 billion, but also rejected a J&J effort to dismiss the jury verdict. The appeal did not involve the question of whether the products caused cancer. Johnson & Johnson wanted...
Source: Asbestos and Mesothelioma News - June 2, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

Memorial Sloan Kettering Opening New Mesothelioma Clinical Trial
Memorial Sloan Kettering Cancer Center in New York City will begin recruiting soon for its latest clinical trial involving patients with malignant pleural mesothelioma and the expanded use of immunotherapy. The single-center, phase I study will explore the effectiveness of pembrolizumab in combination with intensity-modulated pleural radiation therapy, known as IMPRINT, in treating unresectable disease. Pembrolizumab, also known by the brand name Keytruda, was approved by the U.S. Food and Drug Administration in 2020 for treatment of a small subset of mesothelioma patients. As a well-known immunotherapy drug, pemb...
Source: Asbestos and Mesothelioma News - May 26, 2021 Category: Environmental Health Authors: Matt Bardsley Source Type: news

MD Anderson Examines Aggressive Mesothelioma Surgery in Latest Study
A retrospective study involving two decades of pleural mesothelioma patients at the heralded University of Texas MD Anderson Cancer Center failed to demonstrate a definitive survival advantage to support regular use of extrapleural pneumonectomy surgery. The most aggressive surgery possible for this type of mesothelioma – once the surgery of choice – showed no clear benefit over a more conservative procedure. When compared to the less-aggressive, lung-sparing pleurectomy and decortication surgery, EPP had a much higher perioperative mortality rate and a shorter median survival. “In comparison, we...
Source: Asbestos and Mesothelioma News - May 25, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news